Literature DB >> 25167898

mTOR inhibitors and their role in modern concepts of immunosuppression.

Björn Nashan1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25167898     DOI： 10.1007/s00268-014-2756-z

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  14 in total

1.  Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

Authors:  H Tedesco Silva; D Cibrik; T Johnston; E Lackova; K Mange; C Panis; R Walker; Z Wang; G Zibari; Y S Kim
Journal:  Am J Transplant       Date:  2010-04-28       Impact factor: 8.086

2.  Preliminary report of major surgery in liver transplant recipients receiving m-TOR inhibitors without therapeutic discontinuation.

Authors:  Lilian Schwarz; François Cauchy; Filomena Conti; Ailton Sepulveda; Fabiano Perdigao; Denis Bernard; Yvon Calmus; Olivier Soubrane; Olivier Scatton
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

Review 3.  Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.

Authors:  Björn Nashan; Robert Gaston; Vincent Emery; Marcus D Säemann; Nicolas J Mueller; Lionel Couzi; Jacques Dantal; Fuad Shihab; Shamkant Mulgaonkar; Yu Seun Kim; Daniel C Brennan
Journal:  Transplantation       Date:  2012-06-15       Impact factor: 4.939

4.  Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain.

Authors:  N Serkova; W Jacobsen; C U Niemann; L Litt; L Z Benet; D Leibfritz; U Christians
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

5.  Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.

Authors:  Stefan Vítko; Raimund Margreiter; Willem Weimar; Jacques Dantal; Dirk Kuypers; Michael Winkler; Ole Øyen; Hendrik G Viljoen; Pavel Filiptsev; Sami Sadek; Yulan Li; Nathalie Cretin; Klemens Budde
Journal:  Am J Transplant       Date:  2005-10       Impact factor: 8.086

Review 6.  Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides.

Authors:  Natalie Serkova; Uwe Christians
Journal:  Curr Opin Investig Drugs       Date:  2003-11

7.  Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation.

Authors:  Andrea Azzola; Adrian Havryk; Prashant Chhajed; Katrin Hostettler; Judith Black; Peter Johnson; Michael Roth; Allan Glanville; Michael Tamm
Journal:  Transplantation       Date:  2004-01-27       Impact factor: 4.939

Review 8.  The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.

Authors:  Goran B Klintmalm; Sammy Saab; Johnny C Hong; Björn Nashan
Journal:  Clin Transplant       Date:  2014-04-21       Impact factor: 2.863

9.  Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.

Authors:  Björn Nashan; John Curtis; Claudio Ponticelli; Georges Mourad; Jonathan Jaffe; Tomas Haas
Journal:  Transplantation       Date:  2004-11-15       Impact factor: 4.939

10.  Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.

Authors:  P De Simone; F Nevens; L De Carlis; H J Metselaar; S Beckebaum; F Saliba; S Jonas; D Sudan; J Fung; L Fischer; C Duvoux; K D Chavin; B Koneru; M A Huang; W C Chapman; D Foltys; S Witte; H Jiang; J M Hexham; G Junge
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086
View more
  2 in total

1.  Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.

Authors:  Bjorn Nashan; Peter Schemmer; Felix Braun; Markus Dworak; Peter Wimmer; Hans Schlitt
Journal:  Trials       Date:  2015-03-26       Impact factor: 2.279

2.  Incarceration of transplanted kidney through incisional hernia.

Authors:  Atta Nawabi; Derek Marlor; Christopher Camarata; Clay D King; Perwaiz Nawabi
Journal:  J Surg Case Rep       Date:  2021-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.